Advertisement

Duration of antibiotic treatment in disseminated Lyme borreliosis: a double-blind, randomized, placebo-controlled, multicenter clinical study

  • J. OksiEmail author
  • J. Nikoskelainen
  • H. Hiekkanen
  • A. Lauhio
  • M. Peltomaa
  • A. Pitkäranta
  • D. Nyman
  • H. Granlund
  • S.-A. Carlsson
  • I. Seppälä
  • V. Valtonen
  • M. Viljanen
Article

Abstract

Despite rather strict recommendations for antibiotic treatment of disseminated Lyme borreliosis (LB), evidence-based studies on the duration of antibiotic treatment are scarce. The aim of this multicenter study was to determine whether initial treatment with intravenous ceftriaxone (CRO) for 3 weeks should be extended with a period of adjunct oral antibiotic therapy. A total of 152 consecutive patients with LB were randomized in a double-blind fashion to receive either amoxicillin (AMOX) 1 g or placebo (PBO) twice daily for 100 days. Both groups received an initial treatment of intravenous CRO 2 g daily for 3 weeks, followed by the randomized drug or PBO. The outcome was evaluated using the visual analogue scale at the follow-up visits. The final analysis included 145 patients, of whom 73 received AMOX and 72 PBO. Diagnoses of LB were categorized as either definite or possible, on the basis of symptoms, signs, and laboratory results. The diagnosis was definite in 52 of the 73 (71.2%) AMOX-treated patients and in 54 of the 72 (75%) PBO patients. Of the patients with definite diagnoses, 62 had neuroborreliosis, 45 arthritis or other musculoskeletal manifestations, and 4 other manifestations of LB. As judged by the visual analogue scale and patient records, the outcome after a 1-year follow-up period was excellent or good in 114 (78.6%) patients, controversial in 14 (9.7%) patients, and poor in 17 (11.7%) patients. In patients with definite LB, the outcome was excellent or good in 49 (92.5%) AMOX-treated patients and 47 (87.0%) PBO patients and poor in 3 (5.7%) AMOX-treated patients and 6 (11.1%) PBO patients (difference nonsignificant, p = 0.49). Twelve months after the end of intravenous antibiotic therapy, the levels of antibodies against Borrelia burgdorferi were markedly decreased in 50% of the patients with definite LB in both groups. The results indicate that oral adjunct antibiotics are not justified in the treatment of patients with disseminated LB who initially receive intravenous CRO for 3 weeks. The clinical outcome cannot be evaluated at the completion of intravenous antibiotic treatment but rather 6–12 months afterwards. In patients with chronic post-treatment symptoms, persistent positive levels of antibodies do not seem to provide any useful information for further care of the patient.

Keywords

Lyme Borreliosis Erythema Migrans AMOX Lyme Arthritis Skin Biopsy Specimen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The authors thank Bristol–Myers Squibb for their AMOX tablets and Roche for covering part of the costs of the study. The language of the manuscript was revised by Simo Merne, MA.

References

  1. 1.
    Wormser GP, Dattwyler RJ, Shapiro ED et al (2006) The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 43:1089–1134PubMedCrossRefGoogle Scholar
  2. 2.
    Steere AC, Schoen RT, Taylor E (1987) The clinical evolution of Lyme arthritis. Ann Intern Med 107:725–731PubMedGoogle Scholar
  3. 3.
    Dinser R, Jendro MC, Schnar S, Zedler H (2005) Antibiotic treatment of Lyme borreliosis: what is the evidence? Ann Rheum Dis 64:519–523PubMedCrossRefGoogle Scholar
  4. 4.
    Steere AC (2001) Lyme disease. N Engl J Med 345:115–125PubMedCrossRefGoogle Scholar
  5. 5.
    Logigian EL, Kaplan RF, Steere AC (1990) Chronic neurologic manifestations of Lyme disease. N Engl J Med 323:1438–1444PubMedCrossRefGoogle Scholar
  6. 6.
    Kristoferitsch W, Baumhackl U, Sluga E, Stanek G, Zeiler K (1987) High-dose penicillin therapy in meningopolyneuritis Garin–Bujadoux–Bannwarth. Clinical and cerebrospinal fluid data. Zentralbl Bakteriol Mikrobiol Hyg [A] 263:357–364Google Scholar
  7. 7.
    Ziska MH, Donta ST, Demarest FC (1996) Physician preferences in the diagnosis and treatment of Lyme disease in the United States. Infection 24:182–186PubMedCrossRefGoogle Scholar
  8. 8.
    Wahlberg P, Granlund H, Nyman D, Panelius J, Seppälä I (1994) Treatment of late Lyme borreliosis. J Infect 29:255–261PubMedCrossRefGoogle Scholar
  9. 9.
    Donta ST (1997) Tetracycline therapy for chronic Lyme disease. Clin Infect Dis 25(Suppl 1):52–56CrossRefGoogle Scholar
  10. 10.
    Klempner MS, Hu LT, Evans J et al (2001) Two controlled trials of antibiotic treatment in patients with persistent symptoms, and a history of Lyme disease. N Engl J Med 345:85–92PubMedCrossRefGoogle Scholar
  11. 11.
    Sigal LH (2002) Misconceptions about Lyme disease: confusions hiding behind ill-chosen terminology. Ann Intern Med 136:413–419PubMedGoogle Scholar
  12. 12.
    Stanek G, O’Connell S, Cimmino M et al (1996) European Union concerted action on risk assessment in Lyme borreliosis: clinical case definitions for Lyme borreliosis. Wien Klin Wochenschr 108:741–747PubMedGoogle Scholar
  13. 13.
    Viljanen MK, Punnonen J (1989) The effect of storage of antigen-coated polystyrene microwells on the detection of antibodies against Borrelia burgdorferi by enzyme immunoassay (EIA). J Immunol Methods 124:137–141PubMedCrossRefGoogle Scholar
  14. 14.
    Oksi J, Uksila J, Marjamäki M, Nikoskelainen J, Viljanen MK (1995) Antibodies against whole sonicated Borrelia burgdorferi spirochetes, 41 kilodalton flagellin and P39 protein in patients with PCR- or culture-proven late Lyme borreliosis. J Clin Microbiol 33:2260–2264PubMedGoogle Scholar
  15. 15.
    Oksi J, Marttila H, Soini H, Aho H, Uksila J, Viljanen MK (2001) Early dissemination of Borrelia burgdorferi without generalized symptoms in patients with erythema migrans. APMIS 109:581–588PubMedCrossRefGoogle Scholar
  16. 16.
    Halperin JJ, Luft BJ, Anand AK, Rogue CT, Alvarez O, Volkman DJ, Dattwyler RJ (1989) Lyme neuroborreliosis: central nervous system manifestations. Neurology 39:753–759PubMedGoogle Scholar
  17. 17.
    Dattwyler RJ, Wormser GP, Rush TJ et al (2005) A comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wien Klin Wochenschr 117:393–397PubMedCrossRefGoogle Scholar
  18. 18.
    Baranton G, Postic D, Saint-Girons I et al (1992) Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS 461 associated with Lyme borreliosis. Int J Syst Bacteriol 42:378–383PubMedCrossRefGoogle Scholar
  19. 19.
    van Dam AP, Kuiper H, Vos K et al (1993) Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis. Clin Infect Dis 17:708–717PubMedGoogle Scholar
  20. 20.
    Strle F, Ruzic-Sabljic E, Cimperman J, Lotric-Furlan S, Maraspin V (2006) Comparison of findings for patients with Borrelia garinii and Borrelia afzelii isolated from cerebrospinal fluid. Clin Infect Dis 43:704–710PubMedCrossRefGoogle Scholar
  21. 21.
    Krupp LB, Hyman LG, Grimson R et al (2003) Study and treatment of post Lyme disease (STOP-LD). A randomised double masked clinical trial. Neurology 60:1923–1930PubMedGoogle Scholar
  22. 22.
    Kaplan RF, Trevino RP, Johnson GM et al (2003) Cognitive function in post-treatment Lyme disease. Do additional antibiotics help? Neurology 60:1916–1922PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • J. Oksi
    • 1
    Email author
  • J. Nikoskelainen
    • 1
  • H. Hiekkanen
    • 2
  • A. Lauhio
    • 3
  • M. Peltomaa
    • 4
  • A. Pitkäranta
    • 4
  • D. Nyman
    • 5
  • H. Granlund
    • 5
  • S.-A. Carlsson
    • 5
  • I. Seppälä
    • 6
  • V. Valtonen
    • 3
  • M. Viljanen
    • 7
  1. 1.Department of MedicineTurku University Central HospitalTurkuFinland
  2. 2.Department of BiostatisticsUniversity of TurkuTurkuFinland
  3. 3.Division of Infectious Diseases, Department of MedicineHelsinki University Central HospitalHelsinkiFinland
  4. 4.Department of OtorhinolaryngologyHelsinki University Central HospitalHelsinkiFinland
  5. 5.Åland Central HospitalÅlandFinland
  6. 6.HUSLAB Clinical Microbiology LaboratoryHelsinki University Central HospitalHelsinkiFinland
  7. 7.Department of Medical MicrobiologyUniversity of TurkuTurkuFinland

Personalised recommendations